Vertex to Acquire Crinetics Pharmaceuticals for USD 10 Billion
Under the terms of the agreement, Vertex will acquire all outstanding shares of Crinetics for USD 85 per share in cash, representing a net transaction value of approximately USD 8.8 billion after accounting for estimated cash acquired.
Vertex Pharmaceuticals | 08/07/2026 | By Abha
WuXi Biologics and Vertex Pharmaceuticals collaborate to advance a preclinical trispecific T-cell engager targeting B-cell mediated autoimmune diseases under a global licensing agreement.
Vertex Pharmaceuticals | 03/02/2026 | By News Bureau | 216
Vertex Signs Agreement to Acquire Alpine Immune Sciences
Vertex Pharmaceuticals has signed a definitive agreement with Alpine Immune Sciences, a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.
Vertex Pharmaceuticals | 11/04/2024 | By Aishwarya | 910
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy